Denise Myshko

David Blair, CEO of LucyRx, and Jason Borschow, CEO of Abarca, spoke to Managed Healthcare Executive about the company's merger and how the combined company is positioned for the PBM market of the future.

If approved, cemdisiran could be the first RNAi therapeutic to treat generalized myasthenia gravis that would be dosed every 12 weeks.

Aksharananda (Akshar) Rambachan, M.D., an UCSF physician-researcher, says that when used together, the numeric pain score and function scores give clinicians a far more complete clinical picture of a patient's pain.

Hofstra University and Northwell Health's jointly founded medical school has secured funding from the National Institutes of Health for its combined M.D./Ph.D. program.

Survodutide is a dual GLP-1/glucagon receptor agonist that was also able to normalize liver fat in 61% of patients with metabolic dysfunction-associated steatotic liver disease.

If approved to treat patients with mantle cell lymphoma, Brukinsa plus rituximab would be the first chemotherapy-free regimen for newly diagnosed patients.

United Healthcare, Express Scripts, Cigna, Optum Rx and TRICARE offer Neffy without restriction. Neffy is an epinephrine nasal spray available for anaphylaxis.

GLP-1 receptor agonists can help reduce inflammation and improve blood vessel function in patients with peripheral artery disease.

An American Diabetes Association survey has found that high insulin costs are straining patients financially, with 1 in 3 cutting groceries. A new Senate bill aims to limit copays and boost PBM rebate transparency.

Employers cite broker recommendations, cost-control effectiveness, and long-term costs as top factors shaping GLP-1 coverage decisions, according to a new survey from the International Foundation of Employee Benefit Plans.